Tehran University of Medical Sciences

Science Communicator Platform

Share By
Functionalised Nanomaterials for Eradication of Cscs, a Promising Approach for Overcoming Tumour Heterogeneity Publisher Pubmed



Farahmand L1 ; Darvishi B1 ; Salehi M1 ; Samadi Kouchaksaraei S1 ; Majidzadeha K1, 2
Authors

Source: Journal of Drug Targeting Published:2018


Abstract

Today, intratumoural heterogeneity has been recognised as one of the main causes of cancer treatment failure and drug resistance development through which multiple mechanisms are simultaneously involved. From the broad diversity of cells presented in tumour microenvironment, owing to their proliferative potential and longevity, cancer stem cells (CSCs), are the main cell subpopulation involved in tumour development, propagation, metastatic dissemination and induction of intratumoural heterogeneity. Accordingly, selective targeting and eradication of CSCs may represent a promising approach for cancer therapy and evading drug resistance development. Nanotechnology is an attractive outgrowing field in medicine due to its promising capabilities in solving several obstacles associated with conventional chemotherapy agents including poor solubility, lack of selectivity and high systemic toxicity. Accordingly, multiple types of nanocarriers have been successfully developed for improving selective delivery and reducing non-selective toxicities of CSC-specific chemotherapy agents. In Current review, we mostly focus on examining the role of CSCs in development of intratumoral heterogeneity and introducing recently developed nano delivery systems for more efficient targeting and eradication of them. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
6. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)
13. Bacteria and Archaea: A New Era of Cancer Therapy, Journal of Controlled Release (2021)
20. Metallic Nanoparticles for the Modulation of Tumor Microenvironment; a New Horizon, Frontiers in Bioengineering and Biotechnology (2022)